+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID07668154

Evaluating the Safety and Effectiveness of SKB571 Alone or with Pembrolizumab and Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Led by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Updated on 2026-09-09

120

Participants Needed

2

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the drug SKB571 in participants with recurrent or metastatic head and neck squamous cell carcinoma HNSCC that cannot be cured by local therapy or surgery. This Phase II, open-label, multicenter study aims to assess SKB571s effectiveness, safety, tolerability, pharmacokinetics, and immunogenicity in this patient group. The study is sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Participants may receive one of three experimental treatments SKB571 alone, SKB571 combined with pembrolizumab, or SKB571 combined with pembrolizumab and platinum-based chemotherapy carboplatin or cisplatin. Pembrolizumab is given intravenously every 3 weeks for up to about 24 months, while carboplatin or cisplatin is administered intravenously every 3 weeks for up to 6 cycles. SKB571 is given every 3 weeks. Each treatment follows a specific dosing schedule and duration depending on the assigned cohort. During the study, participants will undergo various assessments including tumor measurements by RECIST v1.1, laboratory tests, and monitoring of side effects and drug levels in the blood. Researchers will track outcomes such as objective response rate, progression-free survival, duration of response, disease control rate, overall survival, and immunogenicity for up to 24 months. Safety events and abnormal lab results related to treatment will also be recorded. Participants are expected to comply with the study visits and procedures throughout the trial duration.

CONDITIONS

Brief Title

A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants

Research Team

X

Xin Li

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here